Search Results

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced that it intends to offer and sell shares of its common stock.

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced that it intends to offer and sell shares of its common stock.

Tonix Pharmaceuticals Holding Corp. today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Tonix Pharmaceuticals Holding Corp. today announced data presented at an oral Keynote Talk at the Vaccine Congress 2024 held June 24-25, 2024 in Prague, Czech Republic.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Jessica Morris, Chief Operating Officer, will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, Calif.

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock at an offering price of $1.065 per share.

Tonix Pharmaceuticals Holding Corp. today announced it has entered into a placement agency agreement for the purchase and sale of approximately 7,060,918 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.57 per share (or $0.569 per pre-funded warrant in lieu thereof).

Tonix Pharmaceuticals Holding Corp. today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock.

Tonix Pharmaceuticals Holding Corp. announced the closing of its public offering of 1,199,448 shares of its common stock and pre-funded warrants to purchase up to 2,568,110 shares of common stock in a public offering at an offering price of $1.065 per share of common stock and $1.064 pre-funded warrant.

Tonix Pharmaceuticals Holding Corp. today announced receipt of the formal minutes from a recent pre-New Drug Application (NDA) Type-B Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA) for Tonmya™ for the management of fibromyalgia.